REFERENCES
1. Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of
seasonal influenza in the United States: A tool for strengthening
influenza surveillance and preparedness. Influenza Other Respir
Viruses 2018; 12 : 132-7.
2. Wæhre T, Tunheim G, Bodin JE, et al. Clinical characteristics and
outcomes in hospitalized adult influenza patients: an observational
study from Norway 2014-2018. Infect Dis (Lond) 2022; 54 :
367-77.
3. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical
severity of the SARS-CoV-2 Omicron variant in South Africa.medRxiv 2021: 2021.12.21.21268116.
4. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA
Vaccination and COVID-19 Hospitalization and Disease Severity.JAMA 2021; 326 : 2043-54.
5. Arriola C, Garg S, Anderson EJ, et al. Influenza Vaccination Modifies
Disease Severity Among Community-dwelling Adults Hospitalized With
Influenza. Clin Infect Dis 2017; 65 : 1289-97.
6. Groeneveld GH, Marbus SD, Ismail N, et al. Effectiveness of
oseltamivir in reduction of complications and 30-day mortality in severe
seasonal influenza infection. Int J Antimicrob Agents 2020;56 : 106155.
7. Sharma Y, Horwood C, Hakendorf P, Thompson C. Effectiveness of
Oseltamivir in reducing 30-day readmissions and mortality among patients
with severe seasonal influenza in Australian hospitalized patients.Int J Infect Dis 2021; 104 : 232-8.
8. Segaloff HE, Evans R, Arshad S, et al. The impact of obesity and
timely antiviral administration on severe influenza outcomes among
hospitalized adults. J Med Virol 2018; 90 : 212-8.
9. Wei MY, Luster JE, Chan CL, Min L. Comprehensive review of ICD-9 code
accuracies to measure multimorbidity in administrative data. BMC
Health Serv Res 2020; 20 : 489.
10. Wei MY, Ratz D, Mukamal KJ. Multimorbidity in Medicare
Beneficiaries: Performance of an ICD-Coded Multimorbidity-Weighted
Index. J Am Geriatr Soc 2020; 68 : 999-1006.
11. Segaloff HE, Cheng B, Miller AV, et al. Influenza Vaccine
Effectiveness in the Inpatient Setting: Evaluation of Potential Bias in
the Test-Negative Design by Use of Alternate Control Groups. Am J
Epidemiol 2020; 189 : 250-60.
12. Malosh RE, Martin ET, Callear AP, et al. Respiratory syncytial virus
hospitalization in middle-aged and older adults. J Clin Virol2017; 96 : 37-43.
13. Martin ET, Archer C, McRoberts J, et al. Epidemiology of severe
influenza outcomes among adult patients with obesity in Detroit,
Michigan, 2011. Influenza Other Respir Viruses 2013; 7 :
1004-7.
14. O’Halloran AC, Holstein R, Cummings C, et al. Rates of
Influenza-Associated Hospitalization, Intensive Care Unit Admission, and
In-Hospital Death by Race and Ethnicity in the United States From 2009
to 2019. JAMA Netw Open 2021; 4 : e2121880.
15. Ferdinands JM, Gaglani M, Martin ET, et al. Prevention of Influenza
Hospitalization Among Adults in the United States, 2015-2016: Results
From the US Hospitalized Adult Influenza Vaccine Effectiveness Network
(HAIVEN). J Infect Dis 2019; 220 : 1265-75.
16. Talbot HK, Martin ET, Gaglani M, et al. Coronavirus disease 2019
(COVID-19) Versus Influenza in Hospitalized Adult Patients in the United
States: Differences in Demographic and Severity Indicators. Clin
Infect Dis 2021; 73 : 2240-7.
17. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G.
Simulation-derived best practices for clustering clinical data. J
Biomed Inform 2021; 118 : 103788.
18. Alashwal H, El Halaby M, Crouse JJ, Abdalla A, Moustafa AA. The
Application of Unsupervised Clustering Methods to Alzheimer’s Disease.Front Comput Neurosci 2019; 13 : 31.
19. Ferdinands JM, Gaglani M, Ghamande S, et al. Vaccine Effectiveness
Against Influenza-Associated Hospitalizations Among Adults, 2018-2019,
US Hospitalized Adult Influenza Vaccine Effectiveness Network. J
Infect Dis 2021; 224 : 151-63.
20. Adams K, Tenforde MW, Chodisetty S, et al. A literature review of
severity scores for adults with influenza or community-acquired
pneumonia - implications for influenza vaccines and therapeutics.Hum Vaccin Immunother 2021; 17 : 5460-74.
21. Foundation NK. K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and
stratification. Kidney Disease Outcome Quality Initiative. Am J
Kidney Dis 2002: S1-266.
22. Cross GR, Jain AK. Measurement of Clustering Tendency*. IFAC
Proceedings Volumes 1982; 15 : 315-20.
23. Kaufman L, Rousseeuw PJ. Clustering by means of medoids .
1987; 1987.
24. Segaloff HE, Petrie JG, Malosh RE, et al. Severe morbidity among
hospitalised adults with acute influenza and other respiratory
infections: 2014-2015 and 2015-2016. Epidemiol Infect 2018;146 : 1350-8.
25. Gupta YK, Meenu M, Mohan P. The Tamiflu fiasco and lessons learnt.Indian J Pharmacol 2015; 47 : 11-6.
26. Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on
clinical outcomes at 15 days in patients with severe or critical
coronavirus disease 2019: randomised controlled trial. BMJ 2021;372 : n84.
27. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs
Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe
Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021;181 : 32-40.
28. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in
Observational Studies for Causal Effects. 70 : 41-55.
29. Streiner DL, Norman GR. The pros and cons of propensity scores.Chest 2012; 142 : 1380-2.
30. Domb BG, Sabetian PW. The Blight of the Type II Error: When No
Difference Does Not Mean No Difference. Arthroscopy 2021;37 : 1353-6.
31. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS.
Efficacy and Safety of Oseltamivir in Children: Systematic Review and
Individual Patient Data Meta-analysis of Randomized Controlled Trials.Clin Infect Dis 2018; 66 : 1492-500.
Table 1. Patient characteristics included in k-medoids
algorithm overall by influenza season.